QUOTED. Monika Paule.
Caszyme CEO and 2022 In Vivo Rising Leader Monika Paule is on a mission to expand the CRISPR toolbox of available proteins to enhance diagnostic tools, therapeutics and even agricultural practices.
“Compared with the more common lateral flow test or serology-based diagnostic tools, CRISPR-based diagnostics offer the benefits of greater precision and improved timescales.” – Monica Paule, CEO, Caszyme
Click here for a free trial of Medtech Insight